Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...
Nasdaq Reports February 2026 Volumes NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for February 2026 on its Investor Relations website. A data sheet showing this information can be found at: . About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying markets, technology, data, and advanced analytics that enable our c...
Nasdaq Texas Launches with Inaugural Dual Listings Nasdaq Texas Celebrates Official Launch with the Nasdaq Stock Market Closing Bell at the Alamo with the First Cohort of Dual Listings Nasdaq, Inc. to Dual List on Nasdaq Texas Alongside Inaugural Group SAN ANTONIO, March 05, 2026 (GLOBE NEWSWIRE) -- Nasdaq Texas will mark another milestone by ringing the Nasdaq Closing Bell at The Alamo, San Antonio, Texas, commemorating the 190th anniversary of the Battle of the Alamo and the full operational launch of Nasdaq Texas following approval of its listing rules from the U.S. Securities and Ex...
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s ...
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) -- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting -- BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of p...
Nasdaq Executives to Present at Upcoming Investor Conferences NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) will be presenting at the following conferences in March with webcasts available at Nasdaq’s Investor Relations website: . Who:Sarah Youngwood, Executive Vice President & Chief Financial Officer, NasdaqWhat:Morgan Stanley Technology, Media & Telecom ConferenceWhen:Monday, March 2nd, 11:30 AM ET Who:Jeremy Skule, Executive Vice President, Chief Strategy Officer & Executive Chair, Financial Crime Management Technology, NasdaqWhat:Raymond James 47thAnnual Instituti...
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results — Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. “2025 was a year of disciplined execution for P...
Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date February 13, 2026 NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- At the end of the settlement date of February 13, 2026, short interest in 3,595 Nasdaq Global MarketSM securities totaled 15,834,216,597 shares compared with 15,574,683,465 shares in 3,547 Global Market issues reported for the prior settlement date of January 30, 2026. The mid-January short interest represents 2.25 days compared with 2.58 days for the prior reporting period. Short interest in 1,654 securities on The Nasdaq Capital M...
Nasdaq Raises Medium‑Term Revenue Outlook and Outlines Strategy for Its Next Phase of Scalable Growth at 2026 Investor Day Nasdaq raises medium-term Solutions revenue outlook to 9-12% growthMaintains medium-term outlook for expense growth of 5-8%Company reinforces its position as trusted transformation partner in the AI eraCommits to actioning AI productivity program with an expense efficiency target of $100 million by 2027 NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today will host its Investor Day at 8:00 a.m. ET, where Adena Friedman, Nasdaq Chair and CEO, Sarah ...
A director at American Assets Trust Inc bought 82,386 shares at 19.417USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
HP Inc. Reports Fiscal 2026 First Quarter Results PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- HP (NYSE: HPQ) First quarter GAAP diluted net earnings per share ("EPS") of $0.58, down 1.7% from the prior year period First quarter non-GAAP diluted net EPS of $0.81, up 9.5% from the prior year period First quarter net revenue of $14.4 billion, up 6.9% from the prior-year period First quarter net cash provided by operating activities of $383 million, free cash flow of $175 million First quarter returned $0.6 billion to shareholders in the form of share repurchases and dividends ...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nasdaq, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 February 2026 in which we reassessed the appropriateness of the ratings in the context of t...
A director at MSCI Inc bought 3,681 shares at 543.210USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
A director at Janus Henderson Group Plc sold/sold after exercising options 22,000 shares at 49.271USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.